TRANSCODE THERAPEUTICS INC (RNAZ) Stock News

NASDAQ:RNAZ - US89357L4023 - Common Stock

10.27 USD

+0.01 (+0.1%)

Last: 8/25/2025, 10:53:24 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RNAZ Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: TLX GDTC CLSD IOVA ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

a month ago - By: Benzinga - Mentions: TLX MEIP HCTI ICU ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

4 months ago - By: TransCode Therapeutics, Inc.

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

4 months ago - By: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

4 months ago - By: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

4 months ago - By: TransCode Therapeutics, Inc.

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

4 months ago - By: TransCode Therapeutics, Inc.

News Image

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

4 months ago - By: Zacks Investment Research

All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy

5 months ago - By: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

5 months ago - By: TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering